The Dilemma of Breast Cancer in Males and Research Progress

doi:10.12114/j.issn.1007-9572.2019.00.084

Abstract

Abstract: Breast cancer in men （BCM） is rare and accounts for appropriately 1% of breast cancer（BC）．Compared with breast cancer in women （BCW） BCM is often neglected by clinicians because of its low incidence.Men patients are routinely excluded in most clinical trials of breast cancer treatments，resulting in the dilemma where no clinical guideline could be used to the diagnosis and treatment of BCM.What's more，influenced by Chinese cultural issues，patients with BCM are not willing to talk about breast cancer with their clinicians and it will surely affect the prognosis of BCM.Thus，this study is performed to report updated information about epidemiological characteristics and potential risk factors，clinical manifestations and assessment，pathological features，prognostic factors，treatment and detection，follow-up and prospects after treatment by searching literatures，providing physicians some suggestions and research direction of BCM treatment.

Key words: Breast neoplasms, Male, Diagnosis, Therapy

摘要： 男性乳腺癌（BCM）属于罕见疾病，约占所有乳腺癌（BC）诊断病例的1%。相对于女性乳腺癌（BCW），BCM由于其发病率低的缘故而常被临床医生所忽视，过去绝大多数针对BC的临床试验也通常将男性患者排除在外，从而导致BCM的诊断和治疗陷入了无临床指南可用的现实困境。此外，受到中国文化因素的影响，BCM患者通常不会主动跟医生提及BC相关的临床信息，从而很大程度上影响患者的预后。因此，本文通过文献的搜索，对BCM的流行病学特征及潜在风险因素、临床表现与评估、病理特征、预后影响因素、治疗及检测、治疗后的随访及展望进行了详细的介绍，为临床工作者更好地了解以及治疗BCM提供一些建议和研究方向。

关键词: 乳腺肿瘤, 男性, 诊断, 治疗

YE Zengjie,LIANG Muzi. The Dilemma of Breast Cancer in Males and Research Progress　[J]. Chinese General Practice, 2019, 22(26): 3260-3264. DOI: 10.12114/j.issn.1007-9572.2019.00.084.
叶增杰,梁木子. 男性乳腺癌诊治的现实困境及研究进展[J]. 中国全科医学, 2019, 22(26): 3260-3264. DOI: 10.12114/j.issn.1007-9572.2019.00.084.

References

［1］KORDE L A，ZUJEWSKI J A，KAMIN L，et al．Multidisciplinary meeting on male breast cancer：summary and research recommendations［J］．J Clin Oncol，2010，28（12）：2114-2122．DOI：10.1200/JCO.2009.25.5729.
［2］CHESEBRO A L，RIVES A F，SHAFFER K.Male breast disease：what the radiologist needs to know［J］．Curr Probl Diagn Radiol，2018，S0363-0188（18）：30061-30066．
［3］FENTIMAN I S.The endocrinology of male breast cancer［J］．Endocr Relat Cancer，2018，25（6）：R365-373．
［4］XU R，LI J，ZHANG Y，et al．Male occult breast cancer with axillary lymph node metastasis as the first manifestation：a case report and literature review［J］．Medicine （Baltimore），2017，96（51）：e9312．DOI：10.1097/MD.0000000000009312.
［5］National Cancer Institute.SEER cancer statistics review （CSR） 1975—2014［EB/OL］．（2018-04-02）［2018-06-02］．https：//seer.cancer.gov/csr/1975_2014/.
［6］American Cancer Society.Key statistics for breast cancer in men：cancer facts & figures 2018［EB/OL］．（2018-04-02）［2018-06-02］．https：//www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html.
［7］GIORDANO S H，COHEN D S，BUZDAR A U，et al．Breast carcinoma in men：a population-based study［J］．Cancer，2004，101（1）：51-57．DOI：10.1002/cncr.20312.
［8］O'MALLEY C，SHEMA S，WHITE E，et al．Incidence of male breast cancer in California，1988—2000：racial/ethnic variation in 1759 men［J］．Breast Cancer Res Treat，2005，93（2）：145-150．DOI：10.1007/s10549-005-4517-z.
［9］BRINTON L A，RICHESSON D A，GIERACH G L，et al．Prospective evaluation of risk factors for male breast cancer［J］．J Natl Cancer Inst，2008，100（20）：1477-1481．
［10］ANTONIOU A，PHAROAH P D，NAROD S，et al．Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history：a combined analysis of 22 studies［J］．Am J Hum Genet，2003，72（5）：1117-1130．DOI：10.1086/375033.
［11］DING Y C，STEELE L，KUAN C J，et al．Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States［J］．Breast Cancer Res Treat，2011，126（3）：771-778．DOI：10.1007/s10549-010-1195-2.
［12］THORLACIUS S，STRUEWING J P，HARTGE P，et al．Population-based study of risk of breast cancer in carriers of BRCA2 mutation［J］．Lancet，1998，352（9137）：1337-1339．
［13］TAI Y C，DOMCHEK S，PARMIGIANI G，et al．Breast cancer risk among male BRCA1 and BRCA2 mutation carriers［J］．J Natl Cancer Inst，2007，99（23）：1811-1814．
［14］KWIATKOWSKA E，TERESIAK M，FILAS V，et al．BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients［J］．Clin Cancer Res，2003，9（12）：4452-4459．
［15］DALY M B，PILARSKI R，BERRY M，et al．NCCN guidelines insights：genetic/familial high-risk assessment：breast and ovarian，version 2.2017［J］．J Natl Compr Canc Netw，2017，15（1）：9-20.
［16］MEIJERS-HEIJBOER H，VAN DEN OUWELAND A，KLIJN J，et al．Low-penetrance susceptibility to breast cancer due to CHEK2（*）1100delC in noncarriers of BRCA1 or BRCA2 mutations［J］．Nat Genet，2002，31（1）：55-59．
［17］WASIELEWSKI M，DEN BAKKER M A，VAN DEN OUWELAND A，et al．CHEK2 1100delC and male breast cancer in the Netherlands［J］．Breast Cancer Res Treat，2009，116（2）：397-400．DOI：10.1007/s10549-008-0162-7.
［18］ERKKO H，XIA B，NIKKIL? J，et al．A recurrent mutation in PALB2 in finnish cancer families［J］．Nature，2007，446 （7133）：316-319．DOI：10.1038/nature05609.
［19］CASADEI S，NORQUIST B M，WALSH T，et al．Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer［J］．Cancer Res，2011，71（6）：2222-2229．DOI：10.1158/0008-5472.CAN-10-3958.
［20］ORR N，COOKE R，JONES M，et al．Genetic variants at chromosomes 2q35，5p12，6q25.1，10q26.13，and 16q12.1 influence the risk of breast cancer in men［J］．PLoS Genet，2011，7（9）：e1002290．DOI：10.1371/journal.pgen.1002290.
［21］ORR N，LEMNRAU A，COOKE R，et al．Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk［J］．Nat Genet，2012，44（11）：1182-1184．DOI：10.1038/ng.2417.
［22］FACKENTHAL J D，MARSH D J，RICHARDSON A L，et al．Male breast cancer in Cowden syndrome patients with germline PTEN mutations［J］．J Med Genet，2001，38（3）：159-164．DOI：10.1136/jmg.38.3.159.
［23］LITTLE M P，MCELVENNY D M.Male breast cancer incidence and mortality risk in the Japanese atomic bomb survivors-differences in excess relative and absolute risk from female breast cancer［J］．Environ Health Perspect，2017，125（2）：223-229．
［24］BRINTON L A，KEY T J，KOLONEL L N，et al．Prediagnostic sex steroid hormones in relation to male breast cancer risk［J］．J Clin Oncol，2015，33（18）：2041-2050．
［25］BRINTON L A，COOK M B，MCCORMACK V，et al．Anthropometric and hormonal risk factors for male breast cancer：male breast cancer pooling project results［J］．J Natl Cancer Inst，2014，106（3）：djt465．DOI：10.1093/jnci/djt465.
［26］HULTBORN R，HANSON C，K?PF I，et al．Prevalence of Klinefelter's syndrome in male breast cancer patients［J］．Anticancer Res，1997，17（6D）：4293-4297.
［27］SWERDLOW A J，SCHOEMAKER M J，HIGGINS C D，et al．Cancer incidence and mortality in men with Klinefelter syndrome：a cohort study［J］．J Natl Cancer Inst，2005，97（16）：1204-1210．DOI：10.1093/jnci/dji240.
［28］MAINIERO M B，LOURENCO A P，BARKE L D，et al．ACR appropriateness criteria evaluation of the symptomatic male breast［J］．J Am Coll Radiol，2015，12（7）：678-682．
［29］YEN P P，SINHA N，BARNES P J，et al．Benign and malignant male breast diseases：radiologic and pathologic correlation［J］．Can Assoc Radiol J，2015，66（3）：198-207．
［30］GREIF J M，PEZZI C M，KLIMBERG V S，et al．Gender differences in breast cancer：analysis of 13，000 breast cancers in men from the National Cancer Data Base［J］．Ann Surg Oncol，2012，19（10）：3199-3204.
［31］ANDERSON W F，DEVESA S S.In situ male breast carcinoma in the surveillance，epidemiology，and end results database of the national cancer institute［J］．Cancer，2005，104（8）：1733-1741．DOI：10.1002/cncr.21353.
［32］VERMEULEN MA，SLAETS L，CARDOSO F，et al．Pathological characterisation of male breast cancer：results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program［J］．Eur J Cancer，2017，82（1）：219-227．DOI：10.1016/j.ejca.2017.01.034.
［33］CARDOSO F，BARTLETT J M S，SLAETS L，et al．Characterization of male breast cancer：results of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program［J］．Ann Oncol，2018，29（2）：405-417．
［34］PISCUOGLIO S，NG C K，MURRAY M P，et al．The genomic landscape of male breast cancers［J］．Clin Cancer Res，2016，22（16）：4045-4056．
［35］JOHANSSON I，NILSSON C，BERGLUND P，et al．Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1（NAT1）as a novel prognostic biomarker［J］．Breast Cancer Res，2012，14（1）：R31．DOI：10.1186/bcr3116.
［36］ANDERSON W F，JATOI I，TSE J，et al．Male breast cancer：a population-based comparison with female breast cancer［J］．J Clin Oncol，2010，28（2）：232-239．
［37］MIAO H，VERKOOIJEN H M，CHIA K S，et al．Incidence and outcome of male breast cancer：an international population-based study［J］．J Clin Oncol，2011，29（33）：4381-4386．
［38］SINESHAW H M，FREEDMAN R A，WARD E M，et al．Black/white disparities in receipt of treatment and survival among men with early-stage breast cancer［J］．J Clin Oncol，2015，33（21）：2337-2344．DOI：10.1200/JCO.2014.60.5584.
［39］LEONE J P，LEONE J，ZWENGER A O，et al．Prognostic significance of tumor subtypes in male breast cancer：a population-based study［J］．Breast Cancer Res Treat，2015，152（3）：601-609．DOI：10.1007/s10549-015-3488-y.
［40］AUVINEN A，CURTIS R E，RON E.Risk of subsequent cancer following breast cancer in men［J］．J Natl Cancer Inst，2002，94（17）：1330-1332．DOI：10.1093/jnci/94.17.1330.
［41］HEMMINKI K，SCéLO G，BOFFETTA P，et al．Second primary malignancies in patients with male breast cancer［J］．Br J Cancer，2005，92（7）：1288-1292．
［42］LEONE J P，LEONE J，ZWENGER A O，et al．Locoregional treatment and overall survival of men with T1a，b，cN0M0 breast cancer：a population-based study［J］．Eur J Cancer，2017，71（1）：7-14．DOI：10.1016/j.ejca.2016.10.038.
［43］ZAENGER D，RABATIC B M，DASHER B，et al．Is breast conserving therapy a safe modality for early-stage male breast cancer?［J］．Clin Breast Cancer，2016，16（2）：101-104．
［44］VERONESI U，CASCINELLI N，MARIANI L，et al．Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer［J］．N Engl J Med，2002，347（16）：1227-1232．
［45］MADDEN N A，MACDONALD O K，CALL J A，et al．Radiotherapy and male breast cancer：a population-based registry analysis［J］．Am J Clin Oncol，2016，39（5）：458-462．
［46］GRADISHAR W J，ANDERSON B O，BALASSANIAN R，et al．NCCN guidelines insights：breast cancer，version 1.2017［J］．J Natl Compr Canc Netw，2017，15（4）：433-451.
［47］YILDIRIM E，BERBEROGLU U.Male breast cancer：a 22-year experience［J］．Eur J Surg Oncol，1998，24（6）：548-552.
［48］PEMMARAJU N，MUNSELL M F，HORTOBAGYI G N，et al．Retrospective review of male breast cancer patients：analysis of tamoxifen-related side-effects［J］．Ann Oncol，2012，23（6）：1471-1474．DOI：10.1093/annonc/mdr459.
［49］HARLAN L C，ZUJEWSKI J A，GOODMAN M T，et al．Breast cancer in men in the United States：a population-based study of diagnosis，treatment，and survival［J］．Cancer，2010，116（15）：3558-3568．DOI：10.1002/cncr.25153.
［50］HAYES F J，SEMINARA S B，DECRUZ S，et al．Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback［J］．J Clin Endocrinol Metab，2000，85（9）：3027-3035．DOI：10.1210/jcem.85.9.6795.
［51］PLOURDE P V，DYROFF M，DUKES M.Arimidex：a potent and selective fourth-generation aromatase inhibitor［J］．Breast Cancer Res Treat，1994，30（1）：103-111．
［52］ZAGOURI F，SERGENTANIS T N，CHRYSIKOS D，et al．Fulvestrant and male breast cancer：a pooled analysis［J］．Breast Cancer Res Treat，2015，149（1）：269-275．
［53］TURNER N C，RO J，ANDRé F，et al．Palbociclib in hormone-receptor–positive advanced breast cancer［J］．N Engl J Med，2015，373（3）：209-219．DOI：10.1056/NEJMoa1505270.
［54］MASSARWEH S A，SLEDGE G W，MILLER D P，et al．Molecular characterization and mortality from breast cancer in men［J］．J Clin Oncol，2018，36（14）：1396-1404．
［55］GRALOW J R，BIERMANN J S，FAROOKI A，et al．NCCN task force report：bone health in cancer care［J］．J Natl Compr Canc Netw，2013，11（Suppl 3）：S1-50.
［56］IRANI J，SALOMON L，OBA R，et al．Efficacy of venlafaxine，medroxyprogesterone acetate，and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer：a double-blind，randomised trial［J］．Lancet Oncol，2010，11（2）：147-154．DOI：10.1016/S1470-2045（09）70338-9.
［57］DOEBAR S C，SLAETS L，CARDOSO F，et al．Male breast cancer precursor lesions：analysis of the EORTC 10085/TBCRC/BIG/NABCG international male breast cancer program［J］．Mod Pathol，2017，30（4）：509-518．
［58］CAMERON D，MORDEN J P，CANNEY P，et al．Accelerated versus standard epirubicin followed by cyclophosphamide，methotrexate，and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial （CRUK/05/19）：a multicentre，phase 3，open-label，randomised，controlled trial［J］．Lancet Oncol，2017，18（7）：929-945.
［59］KROP I E，KIM S B，MARTIN A G，et al．Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer （TH3RESA）：final overall survival results from a randomised open-label phase 3 trial［J］．Lancet Oncol，2017，18（6）：743-754．DOI：0.1016/S1470-2045（17）30313-3.
［60］DIéRAS V，MILES D，VERMA S，et al．Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer （EMILIA）：a descriptive analysis of final overall survival results from a randomised，open-label，phase 3 trial［J］．Lancet Oncol，2017，18（6）：732-742．DOI：10.1016/S1470-2045（17）30312-1.

[1]	PAN Ziyun, YIN Hao, LIN Zhirou, MAO Jingyi, HUANG Yan, LUO Yanhua, XIAO Jiafu, HU Yin. From Mechanism to Therapy: Diabetic Autonomic Neuropathy [J]. Chinese General Practice, 2026, 29(21): 2982-2988.
[2]	YAN Wen, ZHANG Hanzhi, JIN Hua, QIAN Jie, YU Dehua. Study on the Diagnosis and Treatment Capacity for Depressive Disorders in Community Health Service Institutions in Shanghai [J]. Chinese General Practice, 2026, 29(20): 2790-2799.
[3]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.
[4]	AN Xian, HUANG Peng, REN Jingjing. Investigation on the Cognition and Current Status of General Practitioners in the Multidisciplinary Diagnosis and Treatment of Medically Unexplained Symptoms [J]. Chinese General Practice, 2026, 29(18): 2472-2481.
[5]	FAN Meixiang, YAN Yunyun, HUANG Yanyan. Interpretation and Discussion of Guidelines for Preventive Activities in General Practice: Bladder Cancer [J]. Chinese General Practice, 2026, 29(18): 2450-2453.
[6]	General Practice Branch of Cross-straits Medicine Exchange Association, General Practice Branch of Zhejiang Medical Association, General Undifferentiated Disease Professional Committee of Zhejiang Society of Mathematical Medicine, Chinese Geriatrics Society. Expert Consensus on the Diagnosis, Treatment, and Management of Numbness (2025) [J]. Chinese General Practice, 2026, 29(18): 2433-2449.
[7]	LUAN Xiaoqing, SUN Jingjing, LI Xiaoling, WANG Manxia. Research Progress on Potential Biomarkers of Neuromyelitis Optica Spectrum Disorder [J]. Chinese General Practice, 2026, 29(17): 2418-2424.
[8]	WANG Yibo, HE Kaiyu, LIANG Guofen, YANG Zhenhua, ZHAO Tingxian, LIAO Biyi, ZHANG La, LIU Shiwei, GONG Xuezhong, LIU Xusheng, GU Yueyu, QIN Xindong, SU Guobin. Diagnosis and Management of Recurrent Urinary Tract Infections in Women: a Comparison and Interpretation Based on Existing Guidelines and Evidence [J]. Chinese General Practice, 2026, 29(17): 2387-2399.
[9]	YAO Dingye, LUO Guiping, SUN Junsheng, LI Hui. Research Progress on Identifying Bipolar Ⅱ Disorder and Depressive Disorder in Primary Care [J]. Chinese General Practice, 2026, 29(15): 2092-2099.
[10]	Nephrology Branch of China Association of Chinese Medicine, Nephrology Committee of Guangdong Provincial Association of Chinese Medicine, SU Peiling, YANG Lihong, BAO Kun. Diagnosis and Treatment Guideline of Integrated Traditional Chinese and Western Medicine for Idiopathic Membranous Nephropathy (2025) [J]. Chinese General Practice, 2026, 29(15): 1953-1970.
[11]	YAN Wenxin, LIU Jue, LIANG Wannian. Perspectives on Key Issues of the General Practice Discipline Development in China [J]. Chinese General Practice, 2026, 29(13): 1649-1653.
[12]	ZHANG Hanzhi, JIN Hua, MA Le, SHI Ling, CHEN Chen, HUAN Hongmei, YU Dehua. Analysis of the Quality of Diagnosis and Treatment of Osteoporosis in Shanghai Community Health Service Institutions [J]. Chinese General Practice, 2026, 29(12): 1548-1557.
[13]	ZHANG Han, ZHANG Hua, CAI Genshen, LIAN Dongbo, ZHANG Jing. Construction of Weight Loss Clinic in Grassroots Medical Institutions and Typical Case Studies [J]. Chinese General Practice, 2026, 29(12): 1520-1524.
[14]	WU Yanyan, DENG Qiancheng, LUO Limin, ZHU Weifang. Clinical Characteristics and Diagnosis and Treatment Analysis of Monkeypox [J]. Chinese General Practice, 2026, 29(11): 1430-1433.
[15]	WANG Yuqi, YE Ruixue, GAO Yan, XUE Kaiwen, ZHOU Jing, LI Dongxia, HAO Yingzi, LI Xiaoxuan, WANG Yulong. Rehabilitation Grading Diagnosis System of the Domestic and Foreign Development Present Situation and Application Requirements [J]. Chinese General Practice, 2026, 29(10): 1250-1255.